NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/27/2023
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Quick snapshot
ST13
US500000097028892Class
Filing
Registration
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Case type
Recorded events
Latest update
Classification
Trademark type
Nice classes
Filing date
Registration date
Expiration date
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Structured fields from the responsible authority and the official record.
Status date
Last transaction
Responsible office
Status code
Official register
Filing basis
First use anywhere
First use in commerce
Drawing code
Owner type
Owner location
Examiner
Law office
Current location
Mark description
The mark consists of the wording "Your Trusted Service Partner for the U.S., Japan, and Asia" in stylized blue font above the wording "Better Medicine Sooner" in stylized light blue font, to the right of an image of the profile of a man running from left to right, appearing to be breaking out from a wall to the left of the man, with both the man and the wall comprised of odd-shaped tiles and pieces in the colors blue, light blue, dark blue, gold, purple, red, and green.
Holders
Representatives
M. Scott Alprin ALPRIN LAW OFFICES, P.C.
Nice Classes
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Business consultancy; marketing research; advertising and promotion services; providing of business information; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs, medical devices and specific foods with governmental regulatory bodies
Class 40
Manufacturing services for others in the field of pharmaceutical products; custom manufacture of pharmaceutical products
Class 42
Testing, inspection or research of pharmaceuticals; testing the functionality of machines and research on machines; development of computer data bases, and updating and maintenance of data in computer data bases in the field of clinical trials; consultation in the field of clinical medical research
Class 44
Providing medical information
Class 45
Preparation of legal documentation for food and drug administrative review
History of USPTO decisions and trademark events.
28 publications found
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/27/2023
REGISTERED-PRINCIPAL REGISTER
06/27/2023
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/24/2023
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/23/2023
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/04/2023
STATEMENT OF USE PROCESSING COMPLETE
05/03/2023
SOU EXTENSION 1 GRANTED
05/03/2023
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/01/2023
SOU EXTENSION 1 FILED
04/25/2023
SOU TEAS EXTENSION RECEIVED
04/25/2023
USE AMENDMENT FILED
04/19/2023
TEAS STATEMENT OF USE RECEIVED
04/19/2023
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/25/2022
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/30/2022
PUBLISHED FOR OPPOSITION
08/30/2022
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/10/2022
APPROVED FOR PUB - PRINCIPAL REGISTER
07/27/2022
EXAMINER'S AMENDMENT ENTERED
07/27/2022
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/27/2022
EXAMINERS AMENDMENT E-MAILED
07/27/2022
EXAMINERS AMENDMENT -WRITTEN
07/27/2022
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/26/2022
NON-FINAL ACTION E-MAILED
06/26/2022
NON-FINAL ACTION WRITTEN
06/26/2022
ASSIGNED TO EXAMINER
06/18/2022
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/22/2021
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/21/2021
NEW APPLICATION ENTERED
09/18/2021
Continuous trademark protection
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.